Treatment of non-psoriatic disease with IFN can induce or exacerbate psoriasis [20]–[23], as can treatment with imiquimod, a toll-like receptor agonist that induces production of type I IFNs from pDCs [24]. The gene discussed is IFNA1; the disease is psoriasis.